| | Title | Author(s) | Year | View Count | | 1 |  | Health-related quality of life of Southern Chinese with chronic hepatitis B infection | Lam, ETP; Lam, CLK; Lai, CL; Yuen, MF; Fong, DYT; So, TMK | 2009 | 375 |
| 2 | | Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B | Yuen, MF; Tanaka, Y; Fong, DYT; Fung, J; Wong, DKH; Yuen, JCH; But, DYK; Chan, AOO; Wong, BCY; Mizokami, M; Lai, CL | 2009 | 439 |
| 3 | | 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B | Liaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV | 2009 | 1,826 |
| 4 | | Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice | Yuen, MF; Lee, SH; Kang, HM; Chung, RK; Kim, J; Ngai, V; Lai, CL | 2009 | 451 |
| 5 | | Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection | Lam, ETP; Lam, CLK; Lai, CL; Yuen, MF; Fong, DYT | 2009 | 441 |
| 6 | | Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy | Shouval, D; Lai, CL; Chang, TT; Cheinquer, H; Martin, P; Carosi, G; Han, S; Kaymakoglu, S; Tamez, R; Yang, J; Tenney, D; BrettSmith, H | 2009 | 66 |
| 7 | | Reply | Yuen, M; Wong, DK; Lai, C | 2009 | 23 |
| 8 | | The duration of lamivudine therapy for chronic hepatitis b: Cessation vs. continuation of treatment after HBeAg seroconversion | Fung, J; Lai, CL; Tanaka, Y; Mizokami, M; Yuen, J; Wong, DKH; Yuen, MF | 2009 | 51 |
| 9 | | Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy | Yuen, MF; Fung, J; Seto, WK; Wong, DKH; Yuen, JCH; Lai, CL | 2009 | 74 |
| 10 |  | Mutational analysis for Wilson's disease | Seto, WK; Mak, CM; But, D; Hung, I; Lam, CW; Tam, S; Yuen, MF; Lai, CL | 2009 | 481 |
| 11 | | Prevention and management of drug resistance for antihepatitis B treatment | Yuen, MF; Fung, J; Wong, DKH; Lai, CL | 2009 | 48 |
| 12 | | New paradigms for the treatment of chronic hepatitis B | Fung, J; Lai, CL; Yuen, MF | 2008 | 107 |
| 13 | | Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis | Fung, J; Lai, CL; Fong, DYT; Yuen, JCH; Wong, DKH; Yuen, MF | 2008 | 388 |
| 14 | | LB80380: A promising new drug for the treatment of chronic Hepatitis B | Fung, J; Lai, CL; Yuen, MF | 2008 | 88 |
| 15 | | Prevalence of fibrosis and cirrhosis in chronic hepatitis B: Implications for treatment and management | Fung, J; Lai, CL; But, D; Wong, D; Cheung, TK; Yuen, MF | 2008 | 294 |
| 16 | | HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma | Yuen, M; Wong, DK; Fung, J; Ip, P; But, D; Hung, I; Lau, K; Yuen, JC; Lai, C | 2008 | 345 |
| 17 | | Telbivudine for chronic hepatitis B: The GLOBE trial | Yuen, MF; Lai, CL | 2008 | 199 |
| 18 | | Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin | Fung, J; Lai, CL; Hung, I; Young, J; Cheng, C; Wong, D; Yuen, MF | 2008 | 305 |
| 19 | | Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report | But, DYK; Lai, CL; Lim, WL; Fung, J; Wong, DKH; Yuen, MF | 2008 | 350 |
| 20 | | Recurrence of hepatitis b-related hepatocellular carcinoma is associated with high viral load at the time of resection | Hung, IFN; Poon, RTP; Lai, CL; Fung, J; Fan, ST; Yuen, MF | 2008 | 249 |
|
